Fig. 1From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final resultsStudy design. a Sample size was based on assuming a best overall response of 70–80% in each cohort. b Recruitment into Cohort 2 began after Cohort 1 had finished enrolling patientsBack to article page